Treating coronary disease and the impact of endothelial dysfunction

Progress in Cardiovascular Diseases

Volumn 57, Issue 5, 2015, Pages 431-442

  Matsuzawa, Yasushi ^a   Guddeti, Raviteja R ^a   Kwon, Taek Geun ^a   Lerman, Lilach O ^a   Lerman, Amir ^a  

^a MAYO CLINIC   (United States)

Author keywords

Atherosclerosis; Cardiovascular disease; Endothelial function; Prognosis

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ALISKIREN; ALPHA GLUCOSIDASE INHIBITOR; ANACETRAPIB; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ARGININE; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CHOLESTEROL ESTER TRANSFER PROTEIN; DALCETRAPIB; DARAPLADIB; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EVACETRAPIB; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; NEBIVOLOL; OMEGA 3 FATTY ACID; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TELMISARTAN; TETRAHYDROBIOPTERIN; TORCETRAPIB; CARDIOVASCULAR AGENT;

ACUTE CORONARY SYNDROME; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR DISEASE ASSESSMENT; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CATHETERIZATION; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; FLOW MEDIATED VASODILATATION; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NON INVASIVE PROCEDURE; PERSONALIZED MEDICINE; PROGNOSIS; REACTIVE HYPEREMIA PERIPHERAL ARTERIAL TONOMETRY; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; ANIMAL; CARDIOVASCULAR SYSTEM EXAMINATION; CORONARY BLOOD VESSEL; CORONARY DISEASE; DRUG EFFECTS; PATHOPHYSIOLOGY; PREDICTIVE VALUE; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

ANIMALS; CARDIOVASCULAR AGENTS; CORONARY DISEASE; CORONARY VESSELS; DIAGNOSTIC TECHNIQUES, CARDIOVASCULAR; ENDOTHELIUM, VASCULAR; HUMANS; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 84924690427     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2014.10.004     Document Type: Article

References (122)

1. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012, 32(9):2045-2051.
2. Puri R., Nissen S.E., Libby P., Shao M., Ballantyne C.M., Barter P.J., et al. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy. Circulation 2013, 128(22):2395-2403.
3. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340(2):115-126.
4. Gossl M., Yoon M.H., Choi B.J., Rihal C., Tilford J.M., Reriani M., et al. Accelerated coronary plaque progression and endothelial dysfunction: serial volumetric evaluation by IVUS. J Am Coll Cardiol Img 2014, 7(1):103-104.
5. Hamburg N.M., Keyes M.J., Larson M.G., Vasan R.S., Schnabel R., Pryde M.M., et al. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. Circulation 2008, 117(19):2467-2474.
6. Bonetti P.O., Lerman L.O., Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003, 23(2):168-175.
7. Kitta Y., Obata J.E., Nakamura T., Hirano M., Kodama Y., Fujioka D., et al. Persistent impairment of endothelial vasomotor function has a negative impact on outcome in patients with coronary artery disease. J Am Coll Cardiol 2009, 53(4):323-330.
8. Modena M.G., Bonetti L., Coppi F., Bursi F., Rossi R. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol 2002, 40(3):505-510.
9. Goff D.C., Lloyd-Jones D.M., Bennett G., O'Donnell C.J., Coady S., Robinson J., et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014, 63(25 Pt B):3026.
10. Khot U.N., Khot M.B., Bajzer C.T., Sapp S.K., Ohman E.M., Brener S.J., et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003, 290(7):898-904.
11. Reriani M.K., Flammer A.J., Jama A., Lerman L.O., Lerman A. Novel functional risk factors for the prediction of cardiovascular events in vulnerable patients following acute coronary syndrome. Circ J 2012, 76(4):778-783.
12. Kent D.M., Hayward R.A. Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. JAMA 2007, 298(10):1209-1212.
13. Pepine C.J. The effects of angiotensin-converting enzyme inhibition on endothelial dysfunction: potential role in myocardial ischemia. Am J Cardiol 1998, 82(10A):23S-27S.
14. Flammer A.J., Anderson T., Celermajer D.S., Creager M.A., Deanfield J., Ganz P., et al. The assessment of endothelial function: from research into clinical practice. Circulation 2012, 126(6):753-767.
15. Anderson T.J., Uehata A., Gerhard M.D., Meredith I.T., Knab S., Delagrange D., et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995, 26(5):1235-1241.
16. Kuvin J.T., Patel A.R., Sliney K.A., Pandian N.G., Sheffy J., Schnall R.P., et al. Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am Heart J 2003, 146(1):168-174.
17. Bonetti P.O., Pumper G.M., Higano S.T., Holmes D.R., Kuvin J.T., Lerman A. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol 2004, 44(11):2137-2141.
18. Lerman A., Zeiher A.M. Endothelial function: cardiac events. Circulation 2005, 111(3):363-368.
19. Little W.C., Downes T.R., Applegate R.J. The underlying coronary lesion in myocardial infarction: implications for coronary angiography. Clin Cardiol 1991, 14(11):868-874.
20. Matsuzawa Y., Sugiyama S., Sumida H., Sugamura K., Nozaki T., Ohba K., et al. Peripheral endothelial function and cardiovascular events in high-risk patients. J Am Heart Assoc 2013, 2(6):e000426.
21. Yeboah J., Crouse J.R., Hsu F.C., Burke G.L., Herrington D.M., Johnson C., Polak J.F., Post W. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation 2007, 115(18):2390-2397.
22. Yeboah J., Folsom A.R., Burke G.L., Johnson C., Polak J.F., Post W., et al. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation 2009, 120(6):502-509.
23. Inaba Y., Chen J.A., Bergmann S.R. Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: a meta-analysis. Int J Cardiovasc Imaging 2010, 26(6):631-640.
24. Ras R.T., Streppel M.T., Draijer R., Zock P.L. Flow-mediated dilation and cardiovascular risk prediction: a systematic review with meta-analysis. Int J Cardiol 2013, 168(1):344-351.
25. Xu Y., Arora R.C., Hiebert B.M., Lerner B., Szwajcer A., McDonald K., et al. Non-invasive endothelial function testing and the risk of adverse outcomes: a systematic review and meta-analysis. Eur Heart J Cardiovasc Imaging 2014, 15(7):736-746.
26. Smith S.C., Benjamin E.J., Bonow R.O., Braun L.T., Creager M.A., Franklin B.A., et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011, 124(22):2458-2473.
27. Bonetti P.O., Lerman L.O., Napoli C., Lerman A. Statin effects beyond lipid lowering-are they clinically relevant?. Eur Heart J 2003, 24(3):225-248.
28. Reriani M.K., Dunlay S.M., Gupta B., West C.P., Rihal C.S., Lerman L.O., et al. Effects of statins on coronary and peripheral endothelial function in humans: a systematic review and meta-analysis of randomized controlled trials. Eur J Cardiovasc Prev Rehabil 2011, 18(5):704-716.
29. Vita J.A., Yeung A.C., Winniford M., Hodgson J.M., Treasure C.B., Klein J.L., et al. Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. Circulation 2000, 102(8):846-851.
30. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366(9493):1267-1278.
31. Cholesterol Treatment Trialists C, Baigent C., Blackwell L., Emberson J., Holland L.E., Reith C., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376(9753):1670-1681.
32. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350(15):1495-1504.
33. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352(14):1425-1435.
34. Barter P.J., Caulfield M., Eriksson M., Grundy S.M., Kastelein J.J., Komajda M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357(21):2109-2122.
35. Simic B., Hermann M., Shaw S.G., Bigler L., Stalder U., Dorries C., et al. Torcetrapib impairs endothelial function in hypertension. Eur Heart J 2012, 33(13):1615-1624.
36. Luscher T.F., Taddei S., Kaski J.C., Jukema J.W., Kallend D., Munzel T., et al. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J 2012, 33(7):857-865.
37. Schwartz G.G., Olsson A.G., Abt M., Ballantyne C.M., Barter P.J., Brumm J., et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012, 367(22):2089-2099.
38. Cannon C.P., Shah S., Dansky H.M., Davidson M., Brinton E.A., Gotto A.M., et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010, 363(25):2406-2415.
39. Hooper L., Thompson R.L., Harrison R.A., Summerbell C.D., Moore H., Worthington H.V., et al. Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database Syst Rev 2004, (4):CD003177.
40. Hu F.B., Bronner L., Willett W.C., Stampfer M.J., Rexrode K.M., Albert C.M., et al. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA 2002, 287(14):1815-1821.
41. He K., Song Y., Daviglus M.L., Liu K., Van Horn L., Dyer A.R., et al. Accumulated evidence on fish consumption and coronary heart disease mortality: a meta-analysis of cohort studies. Circulation 2004, 109(22):2705-2711.
42. Casula M., Soranna D., Catapano A.L., Corrao G. Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: a meta-analysis of randomized, placebo controlled trials. Atheroscler Suppl 2013, 14(2):243-251. [corrected].
43. Wang Q., Liang X., Wang L., Lu X., Huang J., Cao J., et al. Effect of omega-3 fatty acids supplementation on endothelial function: a meta-analysis of randomized controlled trials. Atherosclerosis 2012, 221(2):536-543.
44. Egert S., Stehle P. Impact of n-3 fatty acids on endothelial function: results from human interventions studies. Curr Opin Clin Nutr Metab Care 2011, 14(2):121-131.
45. Finn A.V., Nakano M., Narula J., Kolodgie F.D., Virmani R. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol 2010, 30(7):1282-1292.
46. Kolodgie F.D., Burke A.P., Skorija K.S., Ladich E., Kutys R., Makuria A.T., et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006, 26(11):2523-2529.
47. Schaloske R.H., Dennis E.A. The phospholipase A2 superfamily and its group numbering system. Biochim Biophys Acta 2006, 1761(11):1246-1259.
48. Investigators S., White H.D., Held C., Stewart R., Tarka E., Brown R., et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 2014, 370(18):1702-1711.
49. O'Donoghue M.L., Braunwald E., White H.D., Steen D.P., Lukas M.A., Tarka E., et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA 2014, 312(10):1006-1015.
50. Garg P.K., McClelland R.L., Jenny N.S., Criqui M., Liu K., Polak J.F., et al. Association of lipoprotein-associated phospholipase A(2) and endothelial function in the Multi-Ethnic Study of Atherosclerosis (MESA). Vasc Med 2011, 16(4):247-252.
51. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342(3):145-153.
52. Fox K.M., Investigators EUtOrocewPiscAd Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003, 362(9386):782-788.
53. Watanabe T., Barker T.A., Berk B.C. Angiotensin II and the endothelium: diverse signals and effects. Hypertension 2005, 45(2):163-169.
54. Shahin Y., Khan J.A., Samuel N., Chetter I. Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: a meta-analysis of randomised controlled trials. Atherosclerosis 2011, 216(1):7-16.
55. Li S., Wu Y., Yu G., Xia Q., Xu Y.W. Angiotensin II receptor blockers improve peripheral endothelial function: a meta-analysis of randomized controlled trials. PLoS One 2014, 9(3).
56. Bonadei I., Vizzardi E., D'Aloia A., Sciatti E., Raddino R., Metra M. Role of aliskiren on arterial stiffness and endothelial function in patients with primary hypertension. J Clin Hypertens 2014, 16(3):202-206.
57. Flammer A.J., Gossl M., Li J., Reriani M., Shonyo S., Loeffler D., et al. Renin inhibition with aliskiren lowers circulating endothelial progenitor cells in patients with early atherosclerosis. J Hypertens 2013, 31(3):632-635.
58. Furberg C.D., Psaty B.M., Meyer J.V. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995, 92(5):1326-1331.
59. Poole-Wilson P.A., Lubsen J., Kirwan B.A., van Dalen F.J., Wagener G., Danchin N., et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004, 364(9437):849-857.
60. Dahlof B., Sever P.S., Poulter N.R., Wedel H., Beevers D.G., Caulfield M., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005, 366(9489):895-906.
61. Preston Mason R. Pleiotropic effects of calcium channel blockers. Curr Hypertens Rep 2012, 14(4):293-303.
62. Tang E.H., Vanhoutte P.M. Endothelial dysfunction: a strategic target in the treatment of hypertension?. Pflugers Arch 2010, 459(6):995-1004.
63. Taddei S., Virdis A., Ghiadoni L., Uleri S., Magagna A., Salvetti A. Lacidipine restores endothelium-dependent vasodilation in essential hypertensive patients. Hypertension 1997, 30(6):1606-1612.
64. Investigators E Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). Circulation 2003, 107(3):422-428.
65. Luscher T.F., Pieper M., Tendera M., Vrolix M., Rutsch W., van den Branden F., et al. A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study. Eur Heart J 2009, 30(13):1590-1597.
66. Clarkson P., Mullen M.J., Donald A.E., Powe A.J., Thomson H., Thorne S.A., et al. The effect of amlodipine on endothelial function in young adults with a strong family history of premature coronary artery disease: a randomised double blind study. Atherosclerosis 2001, 154(1):171-177.
67. Gao Y.S., Nagao T., Bond R.A., Janssens W.J., Vanhoutte P.M. Nebivolol induces endothelium-dependent relaxations of canine coronary arteries. J Cardiovasc Pharmacol 1991, 17(6):964-969.
68. Cockcroft J.R., Chowienczyk P.J., Brett S.E., Chen C.P., Dupont A.G., Van Nueten L., et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995, 274(3):1067-1071.
69. Broeders M.A., Doevendans P.A., Bekkers B.C., Bronsaer R., van Gorsel E., Heemskerk J.W., et al. Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production. Circulation 2000, 102(6):677-684.
70. Feuerstein G.Z., Ruffolo R.R. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur Heart J 1995, 16(Suppl. F):38-42.
71. Bank A.J., Kelly A.S., Thelen A.M., Kaiser D.R., Gonzalez-Campoy J.M. Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Hypertens 2007, 20(7):777-783.
72. Harris M.I. Noninsulin-dependent diabetes mellitus in black and white Americans. Diabetes Metab Rev 1990, 6(2):71-90.
73. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352(9131):837-853.
74. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993, 329(14):977-986.
75. Action to Control Cardiovascular Risk in Diabetes Study G, Gerstein H.C., Miller M.E., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358(24):2545-2559.
76. Group A.C., Patel A., MacMahon S., Chalmers J., Neal B., Billot L.., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358(24):2560-2572.
77. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P.D., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360(2):129-139.
78. Reboussin D.M., Goff D.C., Lipkin E.W., Herrington D.M., Summerson J., Steffes M., et al. The combination oral and nutritional treatment of late-onset diabetes mellitus (CONTROL DM) trial results. Diabet Med 2004, 21(10):1082-1089.
79. Torimoto K., Okada Y., Mori H., Tanaka Y. Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus. Cardiovasc Diabetol 2013, 12:1. 10.1186/1475-2840-12-1.
80. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321(7258):405-412.
81. Franklin V.L., Khan F., Kennedy G., Belch J.J., Greene S.A. Intensive insulin therapy improves endothelial function and microvascular reactivity in young people with type 1 diabetes. Diabetologia 2008, 51(2):353-360.
82. Vehkavaara S., Yki-Jarvinen H. 3.5years of insulin therapy with insulin glargine improves in vivo endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol 2004, 24(2):325-330.
83. Potenza M.A., Gagliardi S., Nacci C., Carratu M.R., Montagnani M. Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. Curr Med Chem 2009, 16(1):94-112.
84. Rask-Madsen C., King G.L. Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab 2007, 3(1):46-56.
85. Selvin E., Bolen S., Yeh H.C., Wiley C., Wilson L.M., Marinopoulos S.S., et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 2008, 168(19):2070-2080.
86. Nathanson D., Nystrom T. Hypoglycemic pharmacological treatment of type 2 diabetes: targeting the endothelium. Mol Cell Endocrinol 2009, 297(1-2):112-126.
87. Mather K.J., Verma S., Anderson T.J. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001, 37(5):1344-1350.
88. Pitocco D., Zaccardi F., Tarzia P., Milo M., Scavone G., Rizzo P., et al. Metformin improves endothelial function in type 1 diabetic subjects: a pilot, placebo-controlled randomized study. Diabetes Obes Metab 2013, 15(5):427-431.
89. Vitale C., Mercuro G., Cornoldi A., Fini M., Volterrani M., Rosano G.M. Metformin improves endothelial function in patients with metabolic syndrome. J Intern Med 2005, 258(3):250-256.
90. Kelly A.S., Bergenstal R.M., Gonzalez-Campoy J.M., Katz H., Bank A.J. Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. Cardiovasc Diabetol 2012, 11:64.
91. Phung O.J., Schwartzman E., Allen R.W., Engel S.S., Rajpathak S.N. Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis. Diabet Med 2013, 30(10):1160-1171.
92. Hemmingsen B., Schroll J.B., Lund S.S., Wetterslev J., Gluud C., Vaag A., et al. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus. Cochrane Database Syst Rev 2013, 4:CD009008.
93. Rakel A., Renier G., Roussin A., Buithieu J., Mamputu J.C., Serri O. Beneficial effects of gliclazide modified release compared with glibenclamide on endothelial activation and low-grade inflammation in patients with type 2 diabetes. Diabetes Obes Metab 2007, 9(1):127-129.
94. Lincoff A.M., Wolski K., Nicholls S.J., Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007, 298(10):1180-1188.
95. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356(24):2457-2471.
96. Home P.D., Pocock S.J., Beck-Nielsen H., Curtis P.S., Gomis R., Hanefeld M., et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009, 373(9681):2125-2135.
97. Singh S., Loke Y.K., Furberg C.D. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007, 298(10):1189-1195.
98. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366(9493):1279-1289.
99. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004, 351(11):1106-1118.
100. Ryan M.J., Didion S.P., Mathur S., Faraci F.M., Sigmund C.D. PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension 2004, 43(3):661-666.
101. Hwang J., Kleinhenz D.J., Lassegue B., Griendling K.K., Dikalov S., Hart C.M. Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production. Am J Physiol Cell Physiol 2005, 288(4):C899-C905.
102. Pistrosch F., Passauer J., Fischer S., Fuecker K., Hanefeld M., Gross P. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 2004, 27(2):484-490.
103. Martens F.M., Visseren F.L., de Koning E.J., Rabelink T.J. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J Cardiovasc Pharmacol 2005, 46(6):773-778.
104. Campia U., Matuskey L.A., Panza J.A. Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors. Circulation 2006, 113(6):867-875.
105. Sidhu J.S., Cowan D., Kaski J.C. Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus. Am J Cardiol 2004, 94(2):151-156.
106. Linscheid P., Keller U., Blau N., Schaer D.J., Muller B. Diminished production of nitric oxide synthase cofactor tetrahydrobiopterin by rosiglitazone in adipocytes. Biochem Pharmacol 2003, 65(4):593-598.
107. Standl E., Schnell O., Ceriello A. Postprandial hyperglycemia and glycemic variability: should we care?. Diabetes Care 2011, 34(Suppl. 2):S120-S127.
108. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., Laakso M., et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002, 359(9323):2072-2077.
109. Raz I., Wilson P.W., Strojek K., Kowalska I., Bozikov V., Gitt A.K., et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009, 32(3):381-386.
110. Group N.S., Holman R.R., Haffner S.M., McMurray J.J., Bethel M.A., Holzhauer B., et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010, 362(16):1463-1476.
111. Shimabukuro M., Higa N., Chinen I., Yamakawa K., Takasu N. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. J Clin Endocrinol Metab 2006, 91(3):837-842.
112. Pistrosch F., Schaper F., Passauer J., Koehler C., Bornsteinc S.R., Hanefeld M. Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes. Horm Metab Res 2009, 41(2):104-108.
113. Ban K., Noyan-Ashraf M.H., Hoefer J., Bolz S.S., Drucker D.J., Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117(18):2340-2350.
114. Matsubara J., Sugiyama S., Sugamura K., Nakamura T., Fujiwara Y., Akiyama E., et al. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J Am Coll Cardiol 2012, 59(3):265-276.
115. Advani A., Bugyei-Twum A., Connelly K.A. Cardiovascular effects of incretins in diabetes. Can J Diabetes 2013, 37(5):309-314.
116. Tesauro M., Schinzari F., Adamo A., Rovella V., Martini F., Mores N., et al. Effects of GLP-1 on forearm vasodilator function and glucose disposal during hyperinsulinemia in the metabolic syndrome. Diabetes Care 2013, 36(3):683-689.
117. Nystrom T., Gutniak M.K., Zhang Q., Zhang F., Holst J.J., Ahren B., et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004, 287(6):E1209-E1215.
118. van Poppel P.C., Netea M.G., Smits P., Tack C.J. Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care 2011, 34(9):2072-2077.
119. Matsubara J., Sugiyama S., Akiyama E., Iwashita S., Kurokawa H., Ohba K., et al. Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circ J 2013, 77(5):1337-1344.
120. Preli R.B., Klein K.P., Herrington D.M. Vascular effects of dietary L-arginine supplementation. Atherosclerosis 2002, 162(1):1-15.
121. Ueda S., Matsuoka H., Miyazaki H., Usui M., Okuda S., Imaizumi T. Tetrahydrobiopterin restores endothelial function in long-term smokers. J Am Coll Cardiol 2000, 35(1):71-75.
122. Heitzer T., Krohn K., Albers S., Meinertz T. Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus. Diabetologia 2000, 43(11):1435-1438.